Optimized dengue virus entry inhibitory peptide (10AN)
The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.
1. A peptide entry inhibitor consisting of a peptide with the amino acid sequence of SEQ ID NO: 1.
2. The peptide entry inhibitor of claim 1 , wherein the peptide entry inhibitor inhibits a class II envelope protein.
3. The peptide entry inhibitor of claim 2 , wherein the class II envelope protein is a dengue virus E protein.
4. The peptide entry inhibitor of claim 1 , wherein the peptide entry inhibitor inhibits dengue virus virion:cell fusion.
5. A pharmaceutical composition comprising the peptide entry inhibitor of claim 1 .
6. The pharmaceutical composition of claim 5 further comprising a biocompatible carrier.
7. The pharmaceutical composition of claim 6 , wherein the biocompatible carrier is selected from the group consisting of saline, buffered saline, dextrose and water.